MKI67 and ductal breast carcinoma in situ: Among breast cancers, mutations were detected in patients with the following diagnoses: seven (7/19; 37%) TNBC, four (4/19; 21%) luminal B, three (3/19; 16%) luminal A or B (no data on the Ki67 proliferation index), two (2/19; 10.5%) luminal A, two (2/19; 10.5%) DCIS, and one (1/19; 5%) invasive ductal carcinoma (IDC) with no data on receptor status (Part D in S4 Fig).